Mark A Harris Selected Research

chromium hexavalent ion

1/2020	An adverse outcome pathway for small intestinal tumors in mice involving chronic cytotoxicity and regenerative hyperplasia: a case study with hexavalent chromium, captan, and folpet.
10/2019	Comparison of Gene Expression Responses in the Small Intestine of Mice Following Exposure to 3 Carcinogens Using the S1500+ Gene Set Informs a Potential Common Adverse Outcome Pathway.
1/2018	Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium.
12/2017	Comparison of Toxicity and Recovery in the Duodenum of B6C3F1 Mice Following Treatment with Intestinal Carcinogens Captan, Folpet, and Hexavalent Chromium.
11/2017	Ten factors for considering the mode of action of Cr(VI)-induced gastrointestinal tumors in rodents.
1/2017	Assessment of the mutagenic potential of hexavalent chromium in the duodenum of big blue® rats.
1/2017	High-Throughput Screening Data Interpretation in the Context of In Vivo Transcriptomic Responses to Oral Cr(VI) Exposure.
12/2016	Transcriptomic responses in the oral cavity of F344 rats and B6C3F1 mice following exposure to Cr(VI): Implications for risk assessment.
4/2016	Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium.
8/2015	Duodenal crypt health following exposure to Cr(VI): Micronucleus scoring, γ-H2AX immunostaining, and synchrotron X-ray fluorescence microscopy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark A Harris Research Topics

Disease

22	Neoplasms (Cancer) 01/2020 - 01/2011
11	Hyperplasia 01/2020 - 09/2011
9	Carcinogenesis 10/2019 - 09/2011
4	Intestinal Neoplasms (Intestinal Cancer) 10/2019 - 05/2014
1	Iron Deficiencies 03/2014
1	Anemia 03/2014
1	Carcinoma (Carcinomatosis) 03/2013
1	Adenoma (Adenomas) 03/2013
1	Inflammation (Inflammations) 01/2011

Drug/Important Bio-Agent (IBA)

23	chromium hexavalent ionIBA 01/2020 - 01/2011
15	Drinking WaterIBA 01/2018 - 01/2011
3	CaptanIBA 01/2020 - 12/2017
3	folpet (Phaltan)IBA 01/2020 - 12/2017
3	CarcinogensIBA 10/2019 - 01/2011
3	sodium bichromate (sodium dichromate)IBA 06/2013 - 01/2012
2	DNA (Deoxyribonucleic Acid)IBA 01/2015 - 01/2011
1	MetalsIBA 01/2020
1	Hypoxia-Inducible Factor 1IBA 10/2019
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 10/2019
1	Proteins (Proteins, Gene)FDA Link 01/2017
1	DioxinsIBA 01/2014
1	SoilIBA 01/2014
1	GATIBA 06/2013
1	Codon (Codons)IBA 06/2013
1	IronIBA 01/2012
1	CytokinesIBA 01/2012